VEOS system well received at the NASS 2023 conference in the United States
Sales growth in France
Ecully, November 2, 2023 – Spineway Group, specialist in innovative implants for the treatment of serious spinal pathologies, is pleased to announce that its VEOS posterior spinal fixation system received an excellent response from the spinal implant industry at the North American Spine Society (NASS) Congress in Los Angeles last year. October1.
During the event, the Group received numerous expressions of interest for its VEOS restraint system, which has received 510(k) clearance from the Food and Drug Administration (FDA), and established contacts with potential US partners for its distribution in the USA This innovative platform offers spine surgeons a unique modularity, as the rational organization of the implant and instrument kits allows them to perform many different types of procedures with a single system, both in open and minimally invasive surgery (MIS).
As a reminder, the VEOS range is one of a number of Distimp2 products that now represent a significant part of the Group’s turnover in France. In the first nine months of 2023, Distimp’s sales in France increased by 45% compared to 2022, mainly driven by the success of the VEOS range at a large number of French healthcare institutions, including several university hospitals.
This trend should continue if sales of the VEOS range start in Spain before the end of 2023.
Thanks to these first positive developments, Spineway will continue its development plans, which is a confirmation its goal to become an innovative player in France and internationally, leader in less invasive spine treatments.
Next events: November 10, 2023: Extraordinary General Meeting
SPINEWAY ELIGIBLE FOR PEA-SME (Small and Medium Business Equity Savings Plans) Find out all about Spineway at www.spineway.com
This press release has been drawn up in both English and French. In case of contradictions, the French version shall prevail.
Spineway designs, produces and sells innovative implants and surgical instruments for the treatment of serious spinal conditions. Spineway has an international network of more than 50 independent distributors and 90% of its turnover comes from exports. Spineway, which is eligible for investment through FCPIs (French unit trusts specialized in innovation), has received the OSEO Excellence Award since 2011 and the Deloitte Fast 50 Award (2011). Rhône Alpes INPI Patent Innovation Award (2013) – INPI Talent Award (2015). ISIN: FR001400BVK2 – ALSPW
Contacts:
SPINEWAY
Shareholder services line
Available from Tuesday to Thursday
+33 (0)806 706 060
Eligible PEA/PME
ALSPW
Euronext growth
HEAVEN
Finance & Communications
Relations with investors
Solène Kennis
Spineway@aelium.fr
1 Press release dated October 19, 2023, NASS Congress October 18-20, 2023, Los Angeles, USA. 2 Company acquired in 2021
Kalamazoo, Mich., Nov. 2, 2023 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) reported operating results for the third quarter of 2023:
Third quarter Results
Reported net sales increased9.6% Unpleasant $4.9 billion
Organic net sales increased9.2%
Reported operating profit margin of 19.0%
Adjusted operating income margin(1)increased110 bps to23.4%
Reported earnings per share fell 15.9% to $1.80
Custom EPS(1)increased16.0% Unpleasant $2.46
Overview of net sales growth in the third quarter
Reported
Exchange foreign currencies
Constant currency
Acquisitions / divestments
Biological
MedSurg and neurotechnology
10.5
%
0.2
%
10.3
%
0.2
%
10.1
%
Orthopedics and spine
8.4
0.4
8.0
—
8.0
Total
9.6
%
0.3
%
9.3
%
0.1
%
9.2
%
“We delivered another quarter of strong organic revenue growth and continued margin expansion,” said Kevin A. Lobo, chairman and CEO. “The positive momentum in our business remains intact, including a strong procedural environment and our super cycle of innovation.”
Sales analysis
Consolidated net sales of $4.9 billion increased 9.6% in the quarter and 9.3% at constant exchange rates. Organic net sales increased by 9.2% in the quarter, of which 8.9% due to higher unit volume and 0.3% due to higher prices.
MedSurg and Neurotechnology net sales of $2.9 billion increased 10.5% in the quarter and 10.3% at constant exchange rates. Organic net sales increased by 10.1% in the quarter, of which 8.7% due to higher unit volume and 1.4% due to higher prices.
Orthopedics and Spine net sales of $2.1 billion increased 8.4% in the quarter and 8.0% at constant exchange rates. Organic net sales increased 8.0% in the quarter, of which 9.1% was due to higher unit volume, partially offset by 1.1% due to lower prices.
Revenue Analysis
Reported net income of $692 million fell 15.2% in the quarter. Reported net income per diluted share of $1.80 fell 15.9% in the quarter. Reported gross profit margin and reported operating profit margin were 64.3% and 19.0% in the quarter. The reported net profit includes certain items, such as costs for acquisition and integration-related activities, the amortization of purchased intangible assets, structural optimization and other special costs (including depreciation and impairment of assets), costs to comply with certain regulatory requirements medical devices, recall-related matters, regulatory and legal matters and tax matters. Excluding the above items, adjusted gross profit margin(1) was 64.7% in the quarter, and an adjusted operating income margin(1) amounted to 23.4% in the quarter. Adjusted net profit(1) of $944 million rose 16.5% in the quarter. Adjusted net income per diluted share(1) of $2.46 rose 16.0% in the quarter.
Outlook for 2023
Given our year-to-date performance, robust capital equipment backlog and continued positive procedural trends, we now expect organic net sales growth for full year 2023(2) between 10.0% and 10.5%, including slightly positive prices for the year. If exchange rates remain near their current levels, we expect net sales to be adversely affected by approximately 0.6% and adjusted net earnings per diluted share(2) will be adversely affected by $0.10 to $0.15 for the full year, both of which are included in our guidance. Based on our performance in the first nine months of the year, together with our strong sales momentum, we now expect adjusted net income per diluted share(2) are between $10.35 and $10.45.
(1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net income and adjusted net income per diluted share, with the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net income and net income per diluted share, and other important information are attached to this press release.
(2) We are unable to provide a quantitative reconciliation between our expected net sales growth and expected organic net sales growth because we are unable to estimate with reasonable certainty and without unreasonable effort the impact and timing of acquisitions and divestitures and the impact of foreign currency exchange rates. We are unable to present a quantitative reconciliation between our expected net income per diluted share and expected adjusted net income per diluted share because we cannot estimate with reasonable certainty and without unreasonable effort the impact and timing of structural optimization and other special costs, acquisitions and predict takeovers. -related costs and adjustments to the fair value of inventories and the outcome of certain regulatory, legal and tax matters. The financial impact of these items is uncertain and depends on several factors, including timing, and could be material to our consolidated statements of operations.
Conference call enabled Thursday November 2, 2023
As previously announced, we are organizing a conference call Thursday November 2, 2023 at 4:30 p.m., Eastern Time, to discuss our operating results for the quarter ended September 30, 2023 and provide an operational update.
Register for this conference call at: https://www.veracast.com/webcasts/stryker/events/SYK3Q23.cfm. Once registered, an email confirmation will be sent, including dial-in information and unique conference call access codes required for call entry. Registration is open during the live call. To ensure that you are connected before the start of the call, we recommend that you register at least 15 minutes before the start of the call.
A simultaneous webcast of the call will be accessible via the Investor Relations page of our website at www.stryker.com. For those who do not intend to ask a management question, we recommend listening via the webcast. Please allow 15 minutes to register, download and install the necessary software.
A replay will be available on our website following the conference call for up to one year from the time of the earnings call.
Caution Regarding Forward-Looking Statements
This press release contains information that contains or is based on forward-looking statements within the meaning of the federal securities laws, which are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied by such statements. Such factors include, but are not limited to: weakening of economic conditions, or anticipation thereof, which could adversely affect the level of demand for our products; pricing pressures generally, including cost control measures that could adversely affect the price of or demand for our products; changes in the foreign exchange markets; legislative and regulatory actions; unexpected issues arising in connection with clinical trials and otherwise affecting the approval of new products by the U.S. Food and Drug Administration; inflationary pressure; higher interest rates; supply chain disruptions; changes in reimbursement levels from third-party payers; a significant increase in product liability claims; the final total costs related to recall-related matters; the impact of investigative and legal proceedings and compliance risks; settlement of tax audits; changes in tax laws and regulations; the impact of federal legislation to reform the United States health care system; costs to comply with medical device regulations; changes in the financial markets; changes in our credit ratings; changes in the competitive environment; our ability to integrate and realize the expected benefits of acquisitions in full or within the expected time frames; our ability to achieve expected cost savings; potential negative impacts resulting from environmental, social and governance (ESG) and sustainability issues; the impact on our operations and financial results of a public health emergency and related policies and actions of governments or other third parties; and breaches or failures of our or our suppliers’ information technology systems or products, including through cyber-attacks, data breaches, unauthorized access or theft. Additional information about these and other factors is included in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based or that could affect the likelihood that actual results will occur differ from the results. included in the forward-looking statements.
Stryker is one of the world’s leading medical technology companies, and together with our customers, we are passionate about making healthcare better. We provide innovative products and services in medical, surgical, neurotechnology, orthopedics and spine that help improve patient and healthcare outcomes. In addition to our customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
For investor questions, please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or jason.beach@stryker.com
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or yin.becker@stryker.com
CIRENCESTER, UNITED KINGDOM, November 1, 2023 / EINPresswire.com / — Corin Group, an innovator in orthopedic procedures, is proud to announce 510(k) clearance for its Apollo™ Robotic-Assisted Surgical platform and ApolloKnee™ software application. This marks a major industry milestone in Corin’s continued commitment to helping surgeons increase satisfaction and successful outcomes for their patients when performing total joint replacement surgeries.
Dr. Jim Pierrepont, Global Franchise Lead at Corin Group said: “The Apollo™ platform is the result of the combination of objective planning, precision implementation and continuous learning in the pursuit of forgotten total joint replacement. The Apollo™ platform goes beyond personalized knee alignment during surgery. Corin’s patented BalanceBot™ technology is the first and only system in the world that can achieve personalized dynamic balance for every patient, every time.”
Corin’s experience in this exciting area of robot-assisted total knee arthroplasty (TKA) began with his OMNIBotics® technology, which has gained worldwide recognition for its surgical precision, efficiency and its crucial role in defining dynamic joint balance. The Apollo™ platform, with BalanceBot™ technology, builds on a decade of clinical success to target future improvements in patient outcomes while delivering a more intuitive experience for surgeons.
This approval opens an exciting new chapter in Corin’s innovation journey as the Apollo™ platform technology expands its capabilities into additional clinical applications in joint arthroplasty in the coming years. With the Apollo™ platform leading the way, Corin is uniquely positioned to increase total joint replacement patient satisfaction through objective planning, precision implantation and data-driven continuous learning.
Corin Group Headquartered in Cirencester, UK, with offices around the world, Corin is a fast-growing global company with a vision to advance orthopedics by delivering technology-driven procedures and personalized dynamic balance for any total joint replacement. The unique combination of advanced robotic and AI technologies to plan, implement and learn, along with clinically proven implants, is intended to deliver better outcomes and maximize the value of healthcare for patients, surgeons and healthcare providers.
The Corinium Center Cirencester Gloucestershire, GL7 1YJ For more information about Corin Group, please visit www.coringroup.com and follow us on X and LinkedIn.
BOSTON, November 1, 2023–(BUSINESS WIRE)–Orthopedic surgeon Dr. Daniel Quinn is now using computer-assisted technology to offer guided, personalized surgery for shoulder replacements in the area.
ExactechGPS® Guided personalized surgery is the latest technological advancement that provides surgeons with real-time visual guidance and alignment data in total shoulder surgery.
Much like a navigation device in your car, this platform provides a visual map of the patient’s joint on a screen, allowing surgeons to combine preoperative planning with intraoperative computer-aided technology, to perform implant alignment based on the patient’s needs .
“With GPS, I have complete control over my patients’ shoulder replacement surgery,” said Dr. Quinn. “This technology gives me the ability to connect each patient’s personal plan prior to surgery with real-time intraoperative guidance to ensure proper implant placement. I can be confident that I executed the case exactly as planned, with verified accuracy.”
GPS combines the expertise of surgeons with an advanced computer system to perform the patient’s shoulder surgery with the goal of improved accuracy and precision. GPS is personalized to a patient’s unique bone structure and anatomy and is designed to help surgeons decide where to remove the bone and place the shoulder implant in the optimal position.
The technology’s preoperative planning tool allows surgeons to plan their cases prior to surgery through a virtual simulation. Surgeons can then execute their plan in real time during the operation based on a 3D anatomical model of the patient’s shoulder.
“With the preoperative planning app, I can use my patient’s CT scan to plan the personalized surgery before we even enter the operating room, and I can make adjustments in the operating room as needed,” said Dr. Quinn. “I have read recent studies showing improved clinical outcomes using GPS, and I am pleased that my patients will benefit from using this technology.”
Combined with the Equinoxe® Shoulder System, which has demonstrated excellent biomechanics and results in almost 20 years of use, allows surgeons to combine the best of both worlds: a proven implant base with today’s most advanced surgical technologies.
For more information about GPS or to make an appointment with Dr. Quinn, call 617-964-0024 or visit www.nwoa.com.
Additional information about the technology can be found at www.ExactechGPS.com.
References:
Data registered with Exactech, Inc.
Kida, H. et al. Implications of using a navigation system for glenoid component placement in reverse shoulder arthroplasty. Sci Rep. 2022 Dec 7;12(1):21190
Larose, G. et al. High intraoperative accuracy and low complication rate for computer-aided navigation of the glenoid in total shoulder arthroplasty. JSES. In the press. 2022.
Jones R. et al. Accuracy and precision of glenoid baseplate placement in reverse total shoulder arthroplasty using a novel computer-aided navigation system combined with preoperative planning: a controlled cadaveric study. JSES Seminars in Arthroplasty. 2020 May;30(1):73-82.*
Nashikkar P. et al. The role of intraoperative navigation in glenoid component fixation in reverse total shoulder arthroplasty: a clinical case-control study. J Shoulder elbow surgery. 2019 Sep;28(9):1685-1691.
Youderian A. et al. Two-year clinical outcomes and complications in anatomic and reverse shoulder arthroplasty implanted with Exactech GPS intraoperative navigation. J Shoulder elbow surgery. 2023. In press.
About Exactech
Exactech is a global medical device company that develops and markets orthopedic implant devices, related surgical instruments and Active Intelligence technology.® platform of smart technologies for hospitals and doctors. Headquartered in Gainesville, Florida, Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn, Vumedi, YouTube, Instagram and Tweet. With Exactech by your side you have EXACTLY what you need.
Contacts
Nancy Walsh Sr. Director of Marketing Communications, Exactech Nancy.Walsh@exac.com
KeyLift is the fifth FDA-approved product developed by FloSpine, all invented at Florida Atlantic University® Research Park
BOCA RATON, FLORIDA, USA, November 1, 2023 / EINPresswire.com / — Together with FloSpine, Florida Atlantic University’s Research Park® is pleased to announce that FloSpine has received 510(k) clearance for its KeyLift™ Expandable Interlaminar Stabilization System from the FDA, and has expanded from the Global Ventures entrepreneurial support center into a new, larger office to support growth.
The newly approved device addresses spinal stenosis, a common and debilitating condition that affects more than 100 million people worldwide, resulting in approximately 600,000 surgeries annually in the United States alone. It occurs when the spinal canal narrows, putting pressure on the nerves and causing severe back and leg pain, weakness and numbness. Traditional treatment options for spinal stenosis often involve invasive surgical procedures with long recovery times. The KeyLift System introduces a less invasive alternative, allowing spine and interventional pain physicians to implement this revolutionary treatment in an outpatient surgery center.
The KeyLift Expandable Interlaminar Stabilization System features an innovative, expandable design that enables precise, patient-specific surgical procedures. KeyLift unlocks the biomechanics of the spine and provides three key benefits: 1. Support – KeyLift provides support on the strongest part of the spine, the lamina. This distinguishes it from existing devices that only support the spinous process, which is difficult in patients with osteoporosis. 2. Lift – With the ability to expand up to 4mm in height, KeyLift effectively distracts and relieves nerves, relieving pain caused by spinal stenosis. 3. Stabilize – Positioned closer to the instantaneous axis of rotation of the spine, KeyLift promotes intervertebral disc health by balancing the discs.
This breakthrough technology not only reduces patient discomfort and pain, but also significantly shortens recovery times by being performed in an outpatient surgery center, allowing patients to return to their daily lives more quickly.
The expandable design of the KeyLift system is the result of years of research, development and rigorous testing by the FloSpine team, supported by Luis Escobar, chief design engineer.
“KeyLift offers a more mechanically stable design in a minimally invasive package,” says Dr. Cheng-Lun Soo, MD, orthopedic spine surgeon and co-inventor of the KeyLift. “As a spine surgeon with more than 25 years of experience, I believe this technology will reach more patients by allowing more interventional physicians to treat mild to moderate spinal stenosis without the fear of major surgery.”
Like the four other products invented by FloSpine and approved by the FDA, KeyLift has a Florida-inspired name. FloSpine is committed to advancing spine health care, and to support its continued growth, the company recently expanded its headquarters to a 5,000-square-foot facility in Florida Atlantic University’s Research Park, after completing its scale-up at Global Ventures. The majority of FloSpine’s hiring comes from Florida Atlantic University’s College of Engineering, and over the next two years it plans to expand from 8 to 18 employees.
“This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant market,” said Peter Harris, Founder and CEO of FloSpine. “This marks two significant achievements for our company as we grow in supporting our spine equipment for both interventional pain physicians and spine surgeons. We are confident that KeyLift will become the standard in the treatment of this condition, improving the quality of life for patients overall.”
Andrew Duffell, president of the Research Park at FAU, added, “FloSpine’s growth and expansion of Global Ventures into the Research Park is an inspiration to healthcare entrepreneurs and Florida Atlantic students who see their classmates excel in an exciting, growing industry. We very much look forward to supporting the team as it continues to innovate and contribute to the region’s economy.”
In loving memory of Luis Escobar, Senior Design Engineer and friend.
Andreas Duffel Research Park at FAU +1 561-416-6092 email us here Visit us on social media: Facebook LinkedIn Instagram YouTube
NOTE: This content is not authored or endorsed by “KLST/KSAN”, its advertisers or Nexstar Media Inc.
For questions or corrections to press releases, please contact EIN Presswire.
GAINESVILLE, Fla., November 1, 2023–(BUSINESS WIRE)–Exactech, a developer and manufacturer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced the successful first surgery using its new, advanced Activit-E™ polyethylene for the Truliant® Knee Replacement System.
Hany Bedair, MD, performed the procedure at Massachusetts General Hospital (MGH) in Boston, where the material was developed by noted polyethylene expert Orhun Muratoglu, Ph.D., director of the Harris Orthopedic Laboratory at MGH. Dr. Muratoglu was also present at the knee replacement case.
“It’s a profound moment when the inventor who developed our advanced polyethylene is carried into the case at the hospital where it was developed,” said Adam Hayden, CMO and SVP, Large Joints Business Unit at Exactech. “Exactech is extremely proud to offer this next generation of highly cross-linked polyethylene with vitamin E antioxidant.”
Activit-E provides an optimized balance between material strength and toughness through chemically cross-linked polyethylene, while eliminating the need for gamma radiation technology used in previous generations. It provides active oxidative resistance and a long-lasting, high-quality polyethylene bearing, ultimately providing greater strength and active stabilization.
This new generation of polyethylene is the latest, unique innovation from Dr. Muratoglu and his team, including Ebru Oral, Ph.D., director of biomaterials research. Muratoglu invented the first cross-linked polyethylene, and the first of several generations of vitamin E antioxidant polyethylene for leading orthopedic companies.
“It is exciting to perform the first surgical procedure with an implant material both conceived and developed at our hospital,” said Dr. Bedair. “With this advancement, we expect better results compared to knees with traditional, highly cross-linked polyethylene.”
Activit-E recently received 510(k) clearance from the Food and Drug Administration for Exactech knee and ankle replacements. Activit-E will be on display at the 2023 AAHKS Annual Meeting in Dallas, Texas, November 2-5.
References:
Knight, J, Rodgers III, William P, Freedman, Jordan. “Mixed and Hot Irradiated Versus Infused: Mechanical Properties of Vitamin E Cross-linked UHMWPEs.” ORS Annual Meeting 2017. Poster no. 2034.
Muratoglu, O, Asik, M, Nepple, C, Wannomae, K, Micheli, B, Connolly, R, Oral, E. “Dicumyl peroxide cross-linked UHMWPE/vitamin E blend for total joint arthroplasty implants.” Journal of Orthopedic Research. DOI: 10.1002/jor.25679.
About Exactech
Exactech is a global medical device company that develops and markets orthopedic implant devices, related surgical instruments and Active Intelligence® platform of smart technologies for hospitals and doctors. Headquartered in Gainesville, Florida, Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn, VuMedi, YouTube, Tweet and Instagram. With Exactech by your side you have EXACTLY what you need.
Contacts
Morgan Lee Senior Manager Marketing Communications media@exac.com
MIAMI, Oct. 31, 2023 /PRNewswire/ — On October 14, Dr. Sukdeb Datta of Datta Endoscopic hosted the first annual convention for the American Society of Endoscopic and Interventional Spine Surgery at Datta Endoscopic’s state-of-the-art headquarters in Saddle. Brook, New Jersey, with more than 1,000 online and in-person attendees tuning in for the groundbreaking symposium.
Featuring a line-up of some of the most prominent surgeons from around the world – including keynote speaker and leading international endoscopic spine surgeon, Dr. Kang Taek Lim – the convention has set a new standard for collaboration and technological advancement in the field.
Founded with a mission to facilitate access to emerging spine technology and connect surgeons to new research, the first ASEISS Convention kicked off with a schedule of moderated lectures led by an array of industry experts, including Dr. Kang Taek Lim, Dr. Bong-Soo Kim, Dr. Gabriele Jasper, Dr. Baher Yanni, Dr. Praveen Kadimcherla, Dr. Gautam Das and Dr. (Major) Pankaj Surange. Notable live demonstrations included cadaveric surgical methods for posterior stenotic lumbar decompression (PSLD), anterior cervical endoscopy, and endoscopic spinal fusion.
Annual Interventional Spine Surgery Symposium
“It was a great meeting with so many leaders in the field of endoscopic spine surgery, and an honor to have Dr. Lim,” said spine specialist and participant Dr. Munish Lal from Torrance, California. “I look forward to further training and fellowship under Dr. Datta.”
After celebrating the first of many future successes of the association, this year’s ASEISS guests and faculty have laid a strong foundation for future events, including the association’s monthly International Fellowship Meeting, in which physicians from around the world virtually meet to discuss their respective findings for advancing endoscopic surgical techniques for the spine.
As founder and chairman of ASEISS, Dr. Datta said he couldn’t be more pleased with the success of the association’s first convention. “We are thrilled by the fantastic response from the medical community following our inaugural symposium. This convention reflects the passion, hard work and dedication of our members to advance interventional spine surgery methods for our patients, and we are already looking forward to meeting again next year.”
About ASEISS: The American Society of Endoscopic and Interventional Spine Surgery (ASEISS) is a leading professional organization committed to advancing research, technology and education in endoscopic spine surgery to improve patient care and outcomes. To learn more about the American Society of Endoscopic and Interventional Spine Surgery, and to stay informed about future events and initiatives, visit dattaendoscopic.com/event.
CONTACT: MICHAEL GLOVASKI PHONE: 917.213.4473 EMAIL: 367697@email4pr.com
DRAPER, Utah, Oct. 31, 2023 /PRNewswire/ — Ortho Development Corporation, a designer and manufacturer of orthopedic implants and instruments for hip and knee joint replacement surgery, today announced the launch of BKS® Uni, the latest addition to its portfolio of Balanced Knee® implant systems. BKS Uni is a partial knee replacement system designed to preserve bone, simplify surgical technique and leverage the clinical heritage of the balanced knee system.
Brent Bartholomew, President of Ortho Development said: “The launch of BKS Uni builds on Ortho Development’s legacy of evolutionary innovation. We have developed simple, intuitive implants and instruments to streamline workflow and make a technically demanding operation more predictable. Surgeons and distributors will absolutely love this ASC-friendly dual-tray system.”
The BKS Uni Knee System provides surgeons with a medial fixed-bearing system of implants and instruments designed to allow intraoperative adjustments to enable precise and balanced treatment of unicompartmental knee arthritis.
“The BKS Uni is an intuitive and instrumentally simple system that allows surgeons to adjust the flexion gap to the created extension gap, or vice versa. The simple instrumentation allows surgeons with varying levels of experience with unicondylar knee arthroplasty to achieve efficient and consistent surgical results,” said Dr. Cass Nakasone, orthopedic surgeon at Straub Medical Center in Honolulu, HI.
BKS Uni, in collaboration with other Ortho Development Balanced Knee Solutions, provides surgeons with a continuum of care to treat a wide range of knee pathologies, from partial knee replacements to advanced revision procedures utilizing cones and sleeves, allowing for customized solutions for diverse patient needs.
About Ortho Development Company
Ortho Development Corporation designs, manufactures and distributes orthopedic implants and related surgical instruments. The company’s main product focus is total replacement of knee and hip joints. For more information, visit: www.odev.com.
Castel San Pietro, October 30, 2023 – Medacta Group SA (“Medacta”, SIX: MOVE), a Swiss company providing innovative, personalized and sustainable solutions for joint replacement, sports medicine and spine surgery, is pleased to announce the launch of GMK SpheriKA, the world’s first KA-optimized femoral component indicated for total knee replacement. GMK SpheriKA will make its global debut on November 2 at the American Association of Hip and Knee Surgeons (AAHKS) 2023 Annual Meeting.
“GMK SpheriKA reinforces Medacta’s commitment to providing surgeons with personalized solutions for each of their patients,” says Francesco Siccardi, Chief Executive Officer of Medacta International.“Working with an international team of expert orthopedic surgeons, we have introduced a product that builds on our clinically proven GMK Sphere and incorporates the foundations of Kinematic Alignment to ensure every patient receives an implant that is suitable for his or her unique anatomy.”
Medacta’s continued commitment to making a positive impact on patients requiring a total knee procedure has evolved with the development of the concept of Kinematic Alignment, which restores the original pre-arthritic alignment through anatomical resurfacing, making it ligament release is minimized and more natural knee kinematics are enabled. This approach has been shown to improve patient satisfaction compared to more traditional techniques [1-3]. In recent years, clinical studies have shown that GMK Sphere is a particularly suitable implant for kinematic alignment, with the potential to further improve patient outcomes compared to other knee designs [4-6].
Building on the legacy of the GMK Sphere’s ball-in-socket design, GMK SpheriKA offers patients an implant that potentially feels more natural and stable during daily activities, replicating the movement of the healthy knee.In addition,GMK SpheriKA provides optimized femoral coverage and patellar tracking for kinematic alignment procedures, making it the first implant on the market specifically designed for this technique.
“I am happy to offer the GMK SpheriKA to my patients,” said surgeon developer and Kinematic Alignment pioneer Stephen Howell, MD.“The implant design provides a personalized option that takes into account each patient’s unique anatomy and patellofemoral kinematics, restoring a more normal-feeling knee and quickly returning motion and daily activities.”
MyKA, Medacta’s Kinematic Alignment Platform, offers surgeons the most comprehensive solution for performing Kinematic Alignment safely and reproducibly. In addition to GMK SpheriKA, it includes special instruments and a tailor-made education program offered by the MORE Institute, supported by an international network of expert surgeons. In addition, the platform is enhanced by advanced technologies, such as a special planning protocol for the MyKnee 3D printed patient-tailored manuals and NextAR Knee, our Augmented Reality surgical application, which provides unique real-time data to efficiently supplement the surgical workflow. . Both NextAR Knee and MyKnee are part of the MySolutions Personalized Ecosystem, Medacta’s network of advanced digital solutions designed to improve patient outcomes and healthcare efficiency.
For more information, visit Medacta at AAHKS, Dallas (TX), November 2-5, 2023, at booth #1016, or register at spherika-aahks23.medacta.com to receive updates on GMK’s product developments, resources and events SpheriKA .
REFERENCES [1] Dosset et al. A randomized controlled trial of kinematically and mechanically aligned total knee replacements. Bone Joint J 2014; 96-B: 907–13 [2] Lee et al. Early results of kinematic alignment in primary total knee arthroplasty: a meta-analysis of the literature, The Journal of Arthroplasty 32 (2017) 2028-2032 [3] Yaron, Bar Ziv et al. “Patients undergoing staged bilateral knee arthroplasty are less aware of their kinematically aligned knee compared to their mechanical knee.” Journal of Orthopedics vol. 23 155-159. January 20, 2021 [4] Scott, David F. and Celeste G. Gray. “Results are better with a medially stabilized versus a posteriorly stabilized total knee implanted with kinematic alignment.” The Journal of Arthroplasty 37.8 (2022): S852-S858 [5] Scott, David F. and Amy A. Hellie. “Midflexion, Anteroposterior Stability of Total Knee Replacement Implanted with Kinematic Alignment: A Randomized, Quantitative, Radiographic Laxity Study with Posteriorly Stabilized and Medially Stabilized Implants.” JBJS 105.1 (2023): 9-19. [6] JONES, Brett K.; CARLSON, Brian J.; SCOTT, David F. Better flexion and early recovery with medial stabilized versus single-radius total knee arthroplasty with kinematic alignment: two-year clinical results. The Knee, 2023, 43: 217-223
Contact Medacta International SA Gianluca Olgiati Senior Director of Global Marketing Phone: +41 91 696 60 60 media@medacta.ch
ABOUT MEDACTA Medacta is an international company specialized in the design, production and distribution of innovative orthopedic products, as well as the development of associated surgical techniques. Founded in 1999 in Switzerland, Medacta is active in the fields of joint replacement, spine surgery and sports medicine. Medacta is committed to improving the care and well-being of patients and has a strong focus on the sustainability of healthcare. Medacta’s innovation, created through close collaboration with surgical experts around the world, started with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the MORE Institute, Medacta supports surgeons with a comprehensive and tailor-made program aimed at advancing medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in more than 50 countries. Follow us on Medacta TV, YouTube, LinkedIn and Twitter.
RELATED TRADEMARKS The trademarks related to Medacta Group are in any case registered in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The products and services listed below may be covered by additional trademarks not listed below. Please note that Swiss trademarks may have foreign counterparts. GMK® SpheriKA, GMK® Sphere, MyKA™, MyKnee®MySolutions™ personalized ecosystem, NextAR™ knee.
DISC enhances the patient experience in its new, modern surgery center, built for spine care and orthopedics.
The new, state-of-the-art facility was built to deliver DISC’s unparalleled level of surgical expertise and patient care.
MARINA DEL REY, Calif., Oct. 30, 2023 /PRNewswire/ — DISC Surgery Center in Marina del Rey is accredited by the Accreditation Association for Ambulatory Health Care (AAAHC). The new next-level facility – an 11,000-square-foot ambulatory surgery center (ASC) with two high-tech operating rooms – has undergone and passed AAAHC’s rigorous inspections and meets nationally recognized standards for delivering quality healthcare, as determined by a independent, external evaluation process. DISC Surgery Center in Marina del Rey has achieved the maximum three-year accreditation.
Today’s news underscores DISC parent company TriasMD’s commitment to expanding and giving more people access to a successful ASC model built around the highest level of patient care. Now that DISC Surgery Center in Marina del Rey is officially accredited, the ASC can perform outpatient cases with general anesthesia.
“Now that accreditation is in place, we are actively working with all major insurers to secure in-network contracts for the DISC Surgery Center in Marina del Rey,” said Karen Reiter, TriasMD Vice President of Operations and Payor Management. “We believe that minimally invasive spine surgery, orthopedics and pain management should be more accessible to patients, so we work strategically with payers to ensure our contracts cover the innovative care we provide.”
Although more than 6,100 ambulatory health care organizations in the United States are accredited by AAAHC, the screening is entirely voluntary and not all ASCs that undergo the rigorous evaluation are accredited. AAAHC’s accreditation process includes a comprehensive self-assessment and on-site survey by expert AAAHC surveyors: physicians, nurses and administrators actively involved in outpatient healthcare. The research is advisory and educational, presenting best practices to help an organization improve its care and services. For more information about AAAHC, visit www.aaahc.org.
About DISC Surgery Center in Marina del Rey DISC Surgery Center in Marina del Rey is a purpose-built outpatient clinic focused on the safest, most advanced minimally invasive spine surgery, orthopedic sports medicine, total joint replacement and pain management. DISC is a subsidiary of Trias Global and a portfolio company of Chicago Pacific Founders. For more information, call 310-912-6170, visit discsurgerycenter.com or follow @DISCMD on Instagram.
Media contact: DISC Surgery Center in Marina del Rey 310-930-3445 367705@email4pr.com
